⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

October 22, 2012Cell CycleOpen Access

Cyclin-dependent kinase 4/6 inhibition in cancer therapy

Neil F. Johnson Geoffrey I. Shapiro

View Full Paper

Ask AI

Bookmark

Share

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Abstract

Cyclin-dependent kinases (CDKs) drive cell cycle progression and control transcriptional processes. The dysregulation of multiple CDK family members occurs commonly in human cancer; in particular, ...

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Johnson et al. (2012) studied this question.

synapsesocial.com/papers/6ab74174e7ca7e314dd57aad https://doi.org/10.4161/cc.22390

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

1Discovery of a Potent and Selective Inhibitor of Cyclin-Dependent Kinase 4/6In Vitro Study · 2005 · 507 citations
2Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenograftsOriginal Research · 2004 · 1,240 citations
3Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced CancerEarly-Phase Clinical Trial · 2011 · 366 citations
4Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)Early-Phase Clinical Trial · 2011 · 260 citations
5Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphomaPrognostic Study · 2012 · 299 citations
6Multiple Roles of Cyclin-Dependent Kinase 4/6 Inhibitors in Cancer TherapyOriginal Research · 2012 · 252 citations
7Prolonged early G1 arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle–coupled loss of IRF4Original Research · 2012 · 102 citations
8G-quadruplex ligand-mediated CHK1 and ERα suppression in endocrine-sensitive and endocrine-resistant luminal breast cancer cellsCell Cycle · 2026
9Integrative whole-exome sequencing and functional validation identify drivers of lung cancer metastasis seeding and colonization in the brainCell Cycle · 2026
10Targeting G2/M checkpoint vulnerability in homologous recombination-proficient tumors: lessons from ovarian cancer modelsCell Cycle · 2026

More from Cell Cycle

More from Harvard University

More from Brigham and Women's Hospital

More from Dana-Farber Cancer Institute

More from Dana-Farber Brigham Cancer Center